[go: up one dir, main page]

IT1254915B - Derivati di adenosina ad attivita' a2 agonista - Google Patents

Derivati di adenosina ad attivita' a2 agonista

Info

Publication number
IT1254915B
IT1254915B ITMI920973A ITMI920973A IT1254915B IT 1254915 B IT1254915 B IT 1254915B IT MI920973 A ITMI920973 A IT MI920973A IT MI920973 A ITMI920973 A IT MI920973A IT 1254915 B IT1254915 B IT 1254915B
Authority
IT
Italy
Prior art keywords
agonist
activity
adenosine derivatives
formula
diseases
Prior art date
Application number
ITMI920973A
Other languages
English (en)
Inventor
Gloria Cristalli
Original Assignee
Gloria Cristalli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gloria Cristalli filed Critical Gloria Cristalli
Publication of ITMI920973A0 publication Critical patent/ITMI920973A0/it
Priority to ITMI920973A priority Critical patent/IT1254915B/it
Priority to AT93911492T priority patent/ATE193299T1/de
Priority to ES93911492T priority patent/ES2145774T3/es
Priority to JP5518886A priority patent/JPH07508718A/ja
Priority to PCT/EP1993/000972 priority patent/WO1993022328A1/en
Priority to CA002134067A priority patent/CA2134067A1/en
Priority to DE69328722T priority patent/DE69328722T2/de
Priority to US08/325,201 priority patent/US5593975A/en
Priority to EP93911492A priority patent/EP0637315B1/en
Publication of ITMI920973A1 publication Critical patent/ITMI920973A1/it
Application granted granted Critical
Publication of IT1254915B publication Critical patent/IT1254915B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Derivati d'adenosina ad attività A2 agonista di formula I (FORMULA I) processo per la loro preparazione e composizioni farmaceutiche che li contengono.I composti dell'invenzione sono utili per il trattamento di patologie cardiovascolari e malattie del sistema nervoso.
ITMI920973A 1992-04-24 1992-04-24 Derivati di adenosina ad attivita' a2 agonista IT1254915B (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ITMI920973A IT1254915B (it) 1992-04-24 1992-04-24 Derivati di adenosina ad attivita' a2 agonista
PCT/EP1993/000972 WO1993022328A1 (en) 1992-04-24 1993-04-21 Adenosine derivatives having a2 agonist activity
ES93911492T ES2145774T3 (es) 1992-04-24 1993-04-21 Derivados de adenosina que tienen actividad agonista en a2.
JP5518886A JPH07508718A (ja) 1992-04-24 1993-04-21 Ａ↓２アゴニスト活性を有するアデノシン誘導体
AT93911492T ATE193299T1 (de) 1992-04-24 1993-04-21 Adenosinderivate mit a2 agonistwirkung
CA002134067A CA2134067A1 (en) 1992-04-24 1993-04-21 Adenosine derivatives having a2 agonist activity
DE69328722T DE69328722T2 (de) 1992-04-24 1993-04-21 Adenosinderivate mit a2 agonistwirkung
US08/325,201 US5593975A (en) 1992-04-24 1993-04-21 Adenosine derivatives having A2 agonist activity
EP93911492A EP0637315B1 (en) 1992-04-24 1993-04-21 Adenosine derivatives having a2 agonist activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI920973A IT1254915B (it) 1992-04-24 1992-04-24 Derivati di adenosina ad attivita' a2 agonista

Publications (3)

Publication Number Publication Date
ITMI920973A0 ITMI920973A0 (it) 1992-04-24
ITMI920973A1 ITMI920973A1 (it) 1993-10-24
IT1254915B true IT1254915B (it) 1995-10-11

Family

ID=11363039

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI920973A IT1254915B (it) 1992-04-24 1992-04-24 Derivati di adenosina ad attivita' a2 agonista

Country Status (9)

Country Link
US (1) US5593975A (it)
EP (1) EP0637315B1 (it)
JP (1) JPH07508718A (it)
AT (1) ATE193299T1 (it)
CA (1) CA2134067A1 (it)
DE (1) DE69328722T2 (it)
ES (1) ES2145774T3 (it)
IT (1) IT1254915B (it)
WO (1) WO1993022328A1 (it)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
JP2002173427A (ja) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
MXPA01007850A (es) * 1999-02-01 2002-08-20 Univ Virginia Composiciones para tratar respuesta inflamatoria.
RU2258071C2 (ru) * 1999-05-24 2005-08-10 Юниверсити Оф Вирджиния Пэйтент Фаундейшн Производные 2-алкиниладенозина для борьбы с воспалительной реакцией
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6180615B1 (en) 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
CA2671940A1 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
AU2001278708A1 (en) * 2000-09-08 2002-03-22 Toa Eiyo Ltd. Adenosine derivatives and use thereof
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6726923B2 (en) * 2001-01-16 2004-04-27 Vascular Therapies, Llc Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts
NZ532062A (en) * 2001-10-01 2006-09-29 Univ Virginia 2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
GB0129273D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
KR20050026546A (ko) * 2002-07-29 2005-03-15 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ 수용체 작용제를 이용한 심근 관류 조영
US20050033044A1 (en) * 2003-05-19 2005-02-10 Bristol-Myers Squibb Pharma Company Methods for preparing 2-alkynyladenosine derivatives
CN1890241A (zh) * 2003-10-31 2007-01-03 Cv医药有限公司 A2b腺苷受体拮抗剂
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
SG155182A1 (en) * 2004-08-02 2009-09-30 Univ Virginia 2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
WO2006044856A2 (en) * 2004-10-20 2006-04-27 Cv Therapeuitics, Inc. Use of a2a adenosine receptor agonists
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
KR101494125B1 (ko) * 2006-02-03 2015-02-16 길리애드 사이언시즈, 인코포레이티드 Ａ2ａ-아데노신 수용체 효능제 및 이의 다형체의 제조 방법
WO2007092936A2 (en) * 2006-02-08 2007-08-16 University Of Virginia Patent Foundation Method to treat gastric lesions
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
RU2457209C2 (ru) 2006-04-21 2012-07-27 Новартис Аг Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US20070299089A1 (en) * 2006-06-22 2007-12-27 Cv Therapeutics, Inc. Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
CA2662278C (en) * 2006-09-01 2011-11-22 Cv Therapeutics, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
CN102014959B (zh) 2008-03-10 2016-01-20 康奈尔大学 血脑屏障通透性的调节
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
JP2012532140A (ja) 2009-06-30 2012-12-13 フォレスト・ラボラトリーズ・ホールディングス・リミテッド Ａ２ａｒ作動薬としてのアルコキシ−カルボニル−アミノ−アルキニル−アデノシン化合物及びその誘導体
US9822141B2 (en) 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
NZ703992A (en) 2012-08-01 2018-04-27 Lewis And Clark Pharmaceuticals Inc N-alkyl 2-(disubstituted)alkynyladenosine-5’-uronamides as a2a agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6299395A (ja) * 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
IL84414A0 (en) * 1986-11-14 1988-04-29 Ciba Geigy Ag N9-cyclopentyl-substituted adenine derivatives
PT86660B (pt) * 1987-02-04 1992-02-28 Ciba Geigy Ag Processo para a preparacao de derivados de adenosina-5'-carboxamida
LU87181A1 (fr) * 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
US5034381A (en) * 1988-01-07 1991-07-23 Ciba-Geigy Corporation 2-(substituted amino) adenosines as antihypertensives
ZA902280B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor agents

Also Published As

Publication number Publication date
US5593975A (en) 1997-01-14
ITMI920973A1 (it) 1993-10-24
CA2134067A1 (en) 1993-11-11
ITMI920973A0 (it) 1992-04-24
ATE193299T1 (de) 2000-06-15
WO1993022328A1 (en) 1993-11-11
JPH07508718A (ja) 1995-09-28
EP0637315A1 (en) 1995-02-08
EP0637315B1 (en) 2000-05-24
DE69328722T2 (de) 2000-12-14
DE69328722D1 (de) 2000-06-29
ES2145774T3 (es) 2000-07-16

Similar Documents

Publication Publication Date Title
IT1254915B (it) Derivati di adenosina ad attivita' a2 agonista
NO995006D0 (no) Nye forbindelser
TNSN99191A1 (fr) Derives d'adenine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
PL262105A1 (en) The method of manufacture of new derivatives of benzimidazole
IT1270260B (it) Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi
IT1265101B1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
IT1263089B (it) Composti pirrol-amidinici, processi di preparazione e composizioni farmaceutiche che li contengono.
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
PH25130A (en) 4-acylphenoxy derivatives as anti-inflammatory agents
DE69229339D1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
IT8123940A0 (it) Derivati della s-adenosilmetionina, processo per la loro preparazione e composizioni terapeutiche che licontengono come principio attivo.
TNSN90021A1 (fr) Procede de preparation de tetrahydroimidazo (1,4) benzodiazepin -2- thiones antivirales
DK0736029T3 (da) Antikonvulsive pseudofructopyranosesulfamater
IT1196377B (it) Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche
IT8748404A0 (it) O-alcanoil derivati dell'acido 3ammino-2-idrossipropansolfonico adattivita'anticonvulsivante e loro composizioni farmaceutiche per il trattamento terapeutico dell'epilessia
ITMI931723A1 (it) Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
ITMI931722A1 (it) Derivati della propanammide n-eteroaril sostituiti utili nel trattamento delle malattie cardiovascolari
IT1228437B (it) "derivati di 2,3,4,5,6,7 esaidro 2,7-metano-1,5 benzossazonina (rispettivamente 1,4 benzossazonina), procedimento per la loro preparazione e prodotti medicinali che contengono questi composti.
IT8023601A0 (it) Derivati ammidici dell'acido p-isobutilfenilpropionico, procedimento per la loro preparazione e relative composizioni farmaceutici.
IT1255471B (it) Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
IT1258788B (it) Derivati solforati di acidi biliari
IT1232352B (it) Derivati dell'acido chinurenico ad attivita' sul sistema nervoso centrale, loro preparazione e relative composizioni farmaceutiche
IT1250629B (it) Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
IT8719093A0 (it) Derivati di esteri dell'acido immidazol-1-il-carbossilico, procedimenti per la loro preparazione e composizioni fungicide che contengono il derivato come componente attivo.
IT1247508B (it) Composizioni farmaceutiche contenenti l'estere 4-(2 metilamminoetil)- 1,2- fenilenicodell`acido 2-metilpropanoico per il trattamento della neurootticopatia glaucomatosa

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970329